Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
Abstract Background Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patien...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
BMC
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/6fe58de71bfe4ffa81cf84773b662752 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|